Nyxoah S.A. (Euronext Brussels: NYXH), a health-tech company specializing in the treatment of obstructive sleep apnea (OSA), reported significant financial growth and strategic advancements in its latest earnings call. The company saw a 43% sales increase in the fourth quarter, reaching €4.3 million, and a robust 87% sequential and 42% year-over-year growth in Q4 sales with €1.8 million.
Nyxoah's strategic partnership with ResMed Germany and the completion of enrollment in pivotal U.S. studies signal a strong position as it anticipates Food and Drug Administration (FDA) approval and product launch by the end of 2024.
Key Takeaways
- Nyxoah achieved a 43% increase in sales, with Q4 sales at €1.8 million.
- They are preparing for FDA approval with the submission of PMA modules and expect approval in late 2024 or early 2025.
- The company has a strong cash position with €58 million, providing a financial runway into late 2024.
- Nyxoah holds an estimated 50% market share in Germany and is focused on expanding in Europe.
- They are investing in U.S. commercialization, expecting to onboard commercial leadership by mid-year.
- The company reported positive efficacy and safety data from the DREAM study at the SLEEP 2023 conference.
Company Outlook
- Nyxoah is working towards FDA approval with the submission of the final PMA module planned for Q2 2024.
- The company expects to launch its product by the end of 2024, with FDA approval anticipated in late 2024 or early 2025.
- Nyxoah aims to complete patient follow-up in the DREAM study and complete patient enrollment in the ACCESS study in 2024.
- They are focusing on driving revenue growth in Germany and opening new European markets.
Bearish Highlights
- The German AG&S market saw a decline of approximately 25% from Q4 2022 to Q1 2023, with similar seasonality expected in Q1 2024.
- Nyxoah's gross margin was lower in Q4 due to costs associated with a newly opened manufacturing site in Belgium.
Bullish Highlights
- Nyxoah's partnership with ResMed Germany is expected to bolster OSA therapy penetration and show benefits from Q2 2024.
- The company is investing in manufacturing facilities in Belgium and the U.S. to ensure sufficient inventory for launch.
- Positive DREAM study results have been reported, and detailed data will be presented at the ISSS conference in September.
Misses
- Despite strong sales growth, the company is still in a pre-profit phase with a cash burn of €4.9 million in Q4 2023.
- The gross margin was impacted by the expansion of manufacturing capabilities.
Q&A Highlights
- The burn rate is expected to remain steady in H1 2024 and accelerate in H2 due to U.S. commercialization.
- The DREAM study results will be shared in early April, with a focus on top-line data.
- A 12-month patient follow-up is planned for the ACCESS study, with the aim to submit CCC data for FDA approval as a PMA supplement by mid-2026.
- Nyxoah clarified that the goal of the study is to show equivalent results to unilateral stimulation for non-CCC patients, not to demonstrate superiority.
In conclusion, Nyxoah's strong financial performance and strategic initiatives have positioned the company for potential FDA approval and commercial launch in the near future. With a focus on U.S. commercialization and European market expansion, Nyxoah is poised for continued growth in the OSA therapy market.
InvestingPro Insights
In light of Nyxoah S.A.'s recent financial growth and strategic advancements, several metrics and tips from InvestingPro provide additional context to the company's performance and outlook. With a market capitalization of $398.28 million, the company stands as a notable player in the health-tech industry.
Despite the lack of profitability in the last twelve months, as indicated by a negative P/E ratio of -7.80, Nyxoah's revenue growth has been impressive, with an 84.89% increase in the last twelve months as of Q3 2023.
An InvestingPro Tip that stands out is the company's strong return over the last year, with a 181.43% price total return. This aligns with the company's reported sales increase and strategic partnerships, which may continue to drive investor confidence.
Moreover, Nyxoah's ability to hold more cash than debt on its balance sheet is a positive signal for financial stability, a factor that can be crucial as the company prepares for its anticipated FDA approval and product launch.
Investors looking to delve deeper into Nyxoah's financials and potential can find more InvestingPro Tips. There are 11 additional tips listed on InvestingPro, providing a comprehensive analysis of the company's financial health and market potential. For those interested in gaining an edge in their investment decisions, using the coupon code PRONEWS24 will grant an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This offer can help investors access valuable insights and data to inform their investment strategies.
Full transcript - Nyxoah SA (NYXH) Q4 2023:
Operator: Good day and thank you for standing by. Welcome to Nyxoah Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. [Operator Instructions]. Please note that today's conference is being recorded. I would now like to pass the call over to the Investor Relations and Communications Manager, Mikaela Kirkwood.
Mikaela Kirkwood: Thank you, Carmen. Good evening, and good afternoon, and welcome to our earnings call for the fourth quarter and financial year of 2023. I am Mikaela Kirkwood, Investor Relations and Communications Manager at Nyxoah. Participating from the Company today will be Olivier Taelman, Chief Executive Officer; and Loïc Moreau, Chief Financial Officer. During the call, we will discuss our operating activities and review our fourth quarter financial results released after U.S. market closed today, after which we will host a question-and-answer session. The press release can be found on the Investor Relations section of our website. This call is being recorded and will be archived in the Events section of the Investor Relations tab of our website. Before we begin, I would like to remind you that any statements that relate to expectations or predictions of future events, market trends, results or performance are forward-looking statements. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ for those anticipated or implied by these forward-looking statements. All forward-looking statements are based upon current available information, and the company assumes no obligation to update these statements. Accordingly, you should not place undue reliance on these statements. For list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section on our Form 20-F filed with the Securities and Exchange Commission on March 22, 2023. With that, I will now turn the call over to Olivier.
Olivier Taelman: Thank you, Mikaela. Good afternoon, and good evening, everyone, and thank you for joining us for our fourth quarter and financial year of 2023 earnings call. I would like to open with our 2023 accomplishments that have strengthened our confidence for a transformational 2024. Clinically, we completed enrollment in our DREAM U.S. pivotal study in March and initiated enrollment in our excess complete concentric collapse U.S. pivotal study. From a regulatory perspective, we filed the first three modules in the model of PMA submission. The fourth and final module will contain the DREAM safety and efficacy data. Commercially, we reported 2023 sales of €4.3 million, an increase of 43% from 2022, benefiting from our direct-to-consumer initiatives launched early in the year. We also initiated a partnership with ResMed Germany to further increase overall OSA therapy penetration, ensuring that patients have access to the right treatment. Finally, we continued building our U.S. leadership team, strengthening our U.S. presence. Looking ahead 2024 is set to be the most exciting year in company's history. By early April, we expect to report safety and efficacy results from the DREAM study. Our confidence in DREAM outcomes is supported not only by roughly 500 commercial and clinical Genio implants globally, but also by DREAM efficacy and safety data released in a late breaking poster session at SLEEP 2023 in June. In this poster, we reported efficacy data on the first 34 DREAM patients reaching 12-month follow-up, which demonstrated a 65% AHI responder rate, a 76 ODI responder rate, and safety data on all 115 patients enrolled in the study that was in line with expectations. As a reminder, for the trial to be successful, of the 115 patients, at least 62.6% need to be AHI and ODI responders at 12-month follow-up. We anticipate submitting the fourth and final module in our modular PMA filing, which will include DREAM 12-month safety and efficacy data during the second quarter this year. We are preparing for a launch by the end of 2024 as based upon modular PMA review cycle times. We anticipate FDA approval in late 2024 or early 2025 as we do not control FDA timelines. To ensure, we are fully prepared at launch, we are accelerating investments in our U.S. commercial team. We anticipate having the commercial U.S. leadership onboarded by mid-year and bringing on our sales force, patient management teams, and reimbursement specialists during the second half of 2024. The current hypoglossal nerve stimulation market in the U.S. is very concentrated, allowing for a focused launch strategy on high volume sites complemented by robust prior authorization and patient care teams. A streamlined patient referral pathway from SLEEP specialists to these sites will accelerate market growth. A key differentiator of bilateral stimulation to unilateral stimulation is the ability to treat complete concentric collapse of CCC patients. The U.S. ACCESS pivotal study continues to enroll. As a reminder, CCC patients represent approximately 30% of hypoglossal nerve stimulation eligible to treat OSA patients who are contraindicated to commercially available AG&S therapy in the U.S. and do not have suitable treatment options other than major pallet surgery. In the BETTER SLEEP study, we demonstrated bilateral stimulation can treat CCC patients, which led to a complete concentric collapse label expansion in Europe. Recently, Genio's success in treating CCC patients commercially was demonstrated in a real world case series that showed an average Apnea-Hypopnea Index decrease of 73%. The excess primary endpoints are similar to DREAM, with the objective to expand our U.S. labeling to include complete concentric collapse indication and eliminate the need to perform a drug induced SLEEP endoscopy to determine whether a patient has CCC or not. Commercially, the fourth quarter was very strong with sales of €1.8 million showing 87% sequential and 42% year-over-year growth. This is a result of both strong underlying demand for Genio and recent commercial investments including direct-to-consumer online campaigns and a patient top-line. Continued investing in understanding the patient's journey resulted in the launch of a patient helpline and kicking off a ResMed Germany collaboration to ensure every patient gets the most appropriate OSA treatment. This is not only resulting in educating folks by calling the outline, but can be considered a key pillar in our fourth quarter success together with the strong growth of sales and commercial team in Germany is doing. In 2024, the recent ResMed Germany collaboration will further expand the OSA continuum of care, guiding patients to the appropriate therapy. For CPAP quitting patients suffering from moderate to severe OSA, Genio is a solution and for untreated patients CPAP remains the golden standard. We continue to position ourselves as an innovation leader in the obstructive sleep apnea space with always putting patients first and listening to our surgeons. As a result, Genio is a different approach to hypoglossal nerve stimulation with its lead and tough solution. Genio offers patients a leafless full body MRI compatible non-implanted battery solution powered and controlled by a wearable. Thanks to the fully upgradable wearable component, Genio patients can always have access to the most advanced technology without needing another surgery. The recently launched Genio 2.1 enables greater stimulation adjustability and gives patients the autonomy to adjust stimulation amplitude within predefined boundaries. This will definitely help patients that are very sensitive to neurostimulation overall. While the Genio 3.1 implantable stimulator is under regulatory review and will further support or implant for life concept. Future generations of the Genio system will have a more agronomic wearable component [indiscernible] that will adjust stimulation based on sleeping position and provide patients with real time feedback through data collection that will improve the patient experience. We are making strong progress towards our key objectives for 2024, which are to complete patient follow-up in the DREAM U.S. pivotal study and report efficacy and safety data by early April. File the fourth and final module on the model of PMA submission, complete patient enrollment in ACCESS U.S. pivotal study, continue preparations to enter the U.S. market with regulatory, manufacturing and market access readiness and drive further revenue growth in Germany while opening new European markets. With that, I'm pleased to turn the call over to our Chief Financial Officer, Loïc Moreau who will provide a financial update.
Loïc Moreau: Thank you, Olivier. Good day to everyone and thank you for joining us today. Revenue for the fourth quarter ended December 31, 2023, was €1.8 million, a 42% increase over the fourth quarter of 2022 and an 87% increase over the third quarter of 2023. I would like to point out that the fourth quarters benefit the most from seasonality and while we expect a strong year-over-year growth in the first quarter, we anticipate sales to be down sequentially. Total operating loss for the fourth quarter was €10.8 million versus €9.1 million for the fourth quarter of 2022, driven by an acceleration in clinical activities as well as commercial investments in Europe as well as U.S. As of December 31, 2023, cash and financial assets totaled €58 million compared to €95 million on December 31, 2022. During the fourth quarter, our monthly cash burn was €4.9 million, a slight increase from 3Q driven by U.S. commercialization preparation activities. Based on our current cash position, we have runway into late 2024. With that, I will turn the call back over to Olivier.
Olivier Taelman: Thank you, Loïc. As I hope you all agree, we are entering the most exciting time in Nyxoah's history. We are a few weeks away from DREAM clinical data readout, which if positive, should result in obtaining FDA approval in late 2024 or early 2025, depending upon FDA timeline. I look really forward to accelerating investments in the U.S. commercial organization, so we will be ready for the late 2024 launch and continued sales growth in Europe. This concludes the formal part of our presentation. Operator, I will turn the call over to you to begin our Q&A session.
Operator: Thank you so much. [Operator Instructions]. One moment for our first question. That is from Jon Block with Stifel. Please proceed.
Jon Block: Great. Thanks guys. Good afternoon. I'll start the 4Q 2023 top line was certainly solid. I think ahead of most prior estimates and certainly ahead of hours. Olivier, maybe if you could just talk about what was that strength attributable to? Was it the DTC? Was it the ResMed partnership? I think there was a competitor that had some lead issues in Germany, pardon me. So maybe if you could just talk about the main drivers or even rank order them if you can, that'd be helpful as we think about our models.
Olivier Taelman: So thank you, Jon. Thank you for the question. And I can only agree, I think we can say that the fourth quarter was a very strong quarter in Germany. We estimate also that we have nearly took 50% of the German market share in the fourth quarter. Now, the drivers, I think first of all, it's a confirmation that there is a high acceptance from our German physicians. That is one thing. Second, we have the 48 centers that are now fully trained and also implanting. We are offering doctors a patient, a choice in the hypoglossal nerve stimulation implants, and stepping away from an invasive pacemaker solution into a single incision procedure. This is definitely helping. Further, there is the product differentiation, putting patients at the center. And of course, there is the sleep physician focus through DTC. I think those components are really driving our Q4 strong results.
Jon Block: Perfect. Great. That was very helpful. And maybe just to pivot for the second question, you touched on some of the next steps for U.S. approval and then commercialization. Maybe just to probe a little bit more, can you comment on the status of, call it the first three modules, right, that have already been submitted. And then, is there anything new or incremental when we start thinking about the reimbursement path and which road you're going to go down? Thanks for your time guys.
Olivier Taelman: Yes. As you mentioned correctly, in total there are four modules. We have submitted the first three modules already. The fourth and final module will contain the transformed DREAM safety and efficacy data and will be filed shortly in the second quarter. So the first three are done, the fourth will go hand in hand with the DREAM safety data. Now when we are coming to our further market access strategy, because I think that was also part of the question. Currently, we have a team in place that is working to secure reimbursement from both CMS and the commercial payers. That team will also work with customers through the prior authorization process when we launch in the U.S. We are currently also in close conversations at the AAO who will make a recommendation on CPP codes to AMA. There are a few different strategies. One would be using -- another one would be using an existing neuromodulation code that covers off technology very well. But I think most important is that the reimbursement in both scenarios will be in line with current AG&S payment rates. So I hope that is providing your answer, Jon.
Operator: Thank you. One moment for our next question, please. And it's from the line of Ed White with H.C. Wainwright. Please proceed.
Ed White: Hello, thanks for taking my questions. Perhaps if you could just quantify, if you can the impact of seasonality in the first quarter of this year that you're expecting.
Olivier Taelman: Thank you, Ed, for this question. And I think the best place person to answer this is our CFO. So I'll hand it off to you.
Loïc Moreau: Thank you. Thank you, Olivier, and thanks for the question, Ed. So, as you are aware, the fourth quarter seasonality is driven by the phasing of hospital budgets and spending in Germany. And as you know, we do not provide revenue guidance. But last year, if you observe, the German AG&S market declined approximately 25% from the fourth quarter 2022 to the first quarter 2023, and we would anticipate a similar seasonality in the first quarter 2024. Given we still have high customer concentration, the impact of seasonality on our first quarter could be more pronounced. That's what we anticipate.
Ed White: Okay. Thank you. And also, just to clarify, are essentially all of your sales right now coming from Germany? Is there a number you can use to quantify that?
Olivier Taelman: 90% of our sales in Europe are currently in Germany.
Ed White: Okay. Great. Thank you. And my last question is just on the ResMed, how should we be thinking about the ResMed impact on sales so far? What are you seeing? Is there any way to determine if it's having an impact already or if it should be a later in 2024 event? And also, is there the possibility of a ResMed agreement in the U.S. as well?
Loïc Moreau: So thank you again for this question. Olivier again, I will answer this in fact these two questions. So first of all, in ResMed Germany collaboration, we announced the collaboration end of September 2023. We do not expect to see an impact for the first six months. So we are anticipating beginning to realize benefits in the second quarter this year. That is, I think, the answer on the first part. Now the second, do you anticipate also partnering with ResMed in the U.S.? Our strategy is to go direct in the U.S. If there are opportunities to augment direct approach with partnerships like with ResMed touching on their relationship and tapping over their relationships with key physicians, we will definitely explore those in going forward.
Operator: Thank you. One moment for our next question, please. And it's from the line of Ross Osborn with Cantor Fitzgerald. Please proceed.
Ross Osborn: Hey guys, congrats on progress. Thanks for taking our questions. So, starting off just on the U.S. market, would you walk us through how you're thinking about initially commercializing Genio in terms of targeting existing inspire users versus growing the market? Or in other words, getting first time HGNS users to adopt Genio?
Olivier Taelman: Thank you, Ross, for the question. I mean, we are thinking and we are preparing a lot of different strategies on this point, but I can really be precise in the answer. So the U.S. market today is very concentrated. We plan a targeted launch focused on top accounts, which constitute over 85% of current HGNS sales in the U.S. We will have a dedicated sales force sized appropriately for a targeted launch. There will be targeted DTC focus on product differentiation and patient referral pathway. I think this will be a main differentiator to what is happening today. It will be really a targeted DTC focus. We will be engaging with sleep specialists, enabling a steady stream of patient referrals, scalable patient follow-up strategy and sales, marketing and private authorization teams ahead of launch, and more details I'm really happy to share later this year.
Ross Osborn: Okay. Great. And then maybe one more qualifying question on the ResMed partnership. Would you just remind us why they are incentivized to market Genio?
Olivier Taelman: Yes. So in fact, I -- first of all, I would like to maybe -- partnership because through this partnership, we really aim both ResMed and Nyxoah and our patient centric approach, developing a complete OSA ecosystem where patients can be guided to whichever OSA treatment best suits their needs. We will collaborate on DTC initiatives, sales and marketing efforts to target both sleep physicians and ENT surgeons. And I think the goal of this partnership or to expand OSA therapy penetration and increase of market share. Now what are the benefits? I think for Nyxoah, it's pretty obvious that having access to patients who are quitting CPAP that can be offered Genio, this will drive share gains and strengthen our relationship with sleep specialists. For ResMed, benefit from having access to more OSA patients through the ENT surgeons that we are having at Nyxoah also or helpline and increasing sleep specialist capacity by sending CPAP struggling patients who are time consuming to Genio. I think something also not to neglect is the healthcare system benefit, as untreated OSA patients are at high cost, ensuring these patients are optimally treated either with CPAP or with Genio will definitely have a positive impact on reducing healthcare spendings. And overall, this partnership will also increase OSA therapy penetration and will benefit patients.
Operator: Thank you. One moment for our next question, please. And it's from the line of David Rescott with Baird. Please proceed.
David Rescott: Great. Thanks for taking the questions. I know you touched a little bit on the reimbursement landscape in the U.S. again, I know you mentioned that September of last year at AAO there was some discussions around new codes. Can you remind us what specifically are the next steps as you look out over the next several quarters or so around what we'll find out and when we're going to kind of find that update out around what a U.S. reimbursement code would look?
Olivier Taelman: Yes. No, no, definitely. So the next step will be very precise that the AAO will make a recommendation on CPT code to AMA. So from our side, we are working immediately to secure reimbursement from both CMS once we have FDA approval, so that we can immediately start commercializing. And in parallel, of course, preparing also commercial payers and educate and train them on products can also convince them to start reimbursing our technology. Now, our competitor, as you know has done a terrific job educating the commercial payers about the benefits of HGNS resulting in all having HGNS coverage policies. We have already engaged in an informal discussion with the payers and expect those policies. At launch, very precise, we anticipate being reimbursed to prior authorizations and would expect to be included in coverage policies with commercial payers within 12 months afterwards.
David Rescott: Okay. And then, you mentioned some investments in the sales force ahead of the U.S. launch. I heard you also mention some investments in manufacturing. I'm curious what specifically is going on from the manufacturing side? And historically I think you talked about this $4 million of quarterly cash burn. Is that kind of the right way to think about that into 2024? Or should there be some type of acceleration assuming that you continue to invest in some of the sales force and manufacturing capabilities ahead of a U.S. launch? Thank you.
Olivier Taelman: Yes. So, first part is on the manufacturing side, we really invested heavily. So we have now a complete approved site in Belgium manufacturing our products. And next to this, we are working with a service provider in the U.S. that will also manufacturing or will also manufacture our products. So with both sides, we do believe that we totally or completely have de-risked the manufacturing volume capacity, that we will be able to start building inventory before launch. So that at all time when we launch, we will have significant inventory in our possession that there will never be a product shortage in the first 12 months of launch. That is one thing. When it comes to the cost relating to this and the overall spend, Loïc, I'm sure that you would like to comment on this a little bit further.
Loïc Moreau: So you have seen that we burnt €4.9 million in the last quarter of 2023. When we look forward, we expect the burn rate to remain steady for the first half of the year, while we are in fact doing our pre-commercial investments and then when we starting this summer, we expect this burn rate to accelerate as we see more and more investments in U.S. commercialization activities.
Operator: Thank you. One moment for our next question, please. And it's from the line of Adam Maeder with Piper Sandler. Please proceed.
Adam Maeder: Hi, good afternoon. Congrats on the nice finish for the year and the recent progress. And thank you for taking the questions. I wanted to start on the DREAM study and just the disclosure strategy around full DREAM results. So I heard the data should be communicated by early April. Olivier, are you able to talk a little bit more about exactly what's going to be shared at that point in time? Is it simply the top-line information? Will we get additional details? I'm assuming it's going to be messaged in the form of a press release, but maybe just talk about disclosure strategy. And then I have a follow-up. Thank you.
Olivier Taelman: So thank you, Adam, for the question. So as I mentioned, and we will communicate latest beginning of April, the data that will be in a press release followed also by a call. We will be focused on top-line results, AHI reduction, responder rate, ODI reduction. And then we are planning and moving forward to reveal all the data in detail during the ISSS conference in September, where we will have PI talking to the data and the details. So what you can expect is top-line data being released in a press release, followed also by call where there can be more questions and we will be focusing on, in fact, responder rate, AHI reduction, ODI reduction, we will also talk high-level on the safety data that we are having. And then of course, in parallel, we are preparing everything for a publication in a Tier 1 journal.
Adam Maeder: That's perfect. Thank you for the color, Olivier. And then for the follow-up, I wanted to ask about the ACCESS study. I think it was mentioned in the prepared remarks, but was hoping just to get a little bit more granular in terms of enrollment progress in that study. How should we think about potential timelines for enrollment completion and ultimately potential FDA commercial approval for CCC patients? Thanks for taking the questions.
Olivier Taelman: Okay. So, we continue to make progress with the study. We will not disclose the number of patients implanted already, but that being said, we still continue to plan to close all implants by the end of 2024. Then there is a 12-month patient follow-up. So that brings us to the end of 2025. And then the aim is to submit the CCC data as a PMA supplement that should take maximum six to nine-month review period. So we plan to have the label expansion assuming all data are positive mid-2026.
Operator: Thank you. One moment for our next question, please. And it's from the line of Laura Roba with Degroof Petercam. Please proceed.
Laura Roba: Hi, thank you for taking my questions. We see that gross margin was lower in Q4. Could you elaborate a bit on that and on what we could expect for 2024?
Olivier Taelman: Definitely, and this is definitely a question for our CFO.
Loïc Moreau: Thank you. Thank you, Laura. Yes, indeed. We were at 60% in Q4 versus 62% for the rest of the year. Actually, this is explained by our scale and specifically the fact that we have a newly opened manufacturing site in Belgium that is not yet at full capacity. So we see some modest variability quarter-over-quarter. That said, we anticipate the gross margin to increase over the coming quarters as we scale up volumes. Over time, we expect our gross margin to eventually approximate the level of other neural stimulation companies and to be above 80%.
Operator: Thank you so much. And one moment for our next question, please. All right. And our last question will be from Suraj Kalia with Oppenheimer. Please go ahead.
Suraj Kalia: Olivier and Loïc, can you hear me all right?
Olivier Taelman: Yes, we can.
LoïcMoreau: Yes.
Olivier Taelman: Hello.
Suraj Kalia: Pardon the background noise, and congrats on the progress. So Olivier, a few questions from my side as we look forward to DREAM, Olivier, what would you say in your position say the results are -- how do you characterize the delta between bilateral versus unilateral. What would make you say these results are better than unilateral? What would make you say these are somewhat less than unilateral?
Olivier Taelman: So if I understand the question correct Suraj, because there is a little bit background. So you're asking the results, comparison between bilateral result and unilateral result that we are seeing; is this correct?
Suraj Kalia: Yes. I guess what I'm trying to understand, Olivier is, you can rest assured the numbers are going to be sliced and diced 10 different ways to make different arguments, right? I guess what I'm trying to understand is hypothetically; if you have 50% responder rate in the complete cohort inspire had a certain responder rate. We can slice and dice different metrics. What would make you say, you know what the totality of these results show bilateral is better than unilateral? What would make you somewhat cautious and say, you know what, we missed somewhere versus unilateral?
Olivier Taelman: Yes. So first of all, I have to point out that the study was not designed to show superiority and it was even not a head-to-head trial. But on the other hand, you are look at those patients phenotyping. We look at the inclusion criteria; we look at the BMI criteria. So the studies are really similar or comparable. Now, what would we expect? So if we can show, and that's what we already communicated. First of all, of course, reaching the primary endpoint. Second, showing equivalent compared to the unilateral stimulation for non-CCC patients. I think that would be already a first accomplishment. When you look at what the respond rate would mean. In our case, we are forward and we have to show responder rate of 62.6%. So I would like to see numbers, of course, above. That is one thing. And then second, there will also be a lot of analysis that will be done on AHI reduction. What is the AHI reduction for patients with a higher BMI for patients with a BMI that is, for example, 25 and then going lower. So I think this is really important. Let's also not forget the ODI reduction because there is also direct oxygen desaturation and the mortality risk. So I think this is important. And of course, all reductions have to meet the clinically, have to be clinically relevant. So that's what we are looking at. So equivalent that's what we would like to claim. We would further slice and dice the data and looking on AHI reductions. There is also the supine position that we are seeing and how the reduction is this because during a night patients, they tend not to stay only in one position, but to toss and turn a little bit. So also there we will come with a sub analysis. That's what you can expect from our data.
Suraj Kalia: Got it. And Olivier, I'll quickly with my follow-up question and avoid the background noise. So Olivier, do you expect Genio eventually to be used in patients who are unwilling to try CPAP? And also, what has been the experience in Germany? Are they more female gender usage is higher than male just given beard issues? Thank you for taking my questions.
Olivier Taelman: So first of all, we have to follow the current guidelines. And that means that patients need to be refractory of quitting CPAP. So that is one thing. So will we become first line? I think in order to do this; HGNS needs to change those guidelines. But for now it's clear that patients have to have CPAP before they become eligible for an HGNS treatment. So when it comes to the gender of patients, so also there we still see that the majority of patients are male and not female. And when it comes to the fact what you are alluding [Technical Difficulty] we also there we can confirm that patients who are suffering from modern or severe OSA and offer the Genio solutions are really happy to save, if I can say it like this, so that they can really benefit from our technology and from the bilateral stimulation as it is recommended by their surgeon and physician. So I hope that this is answering your question.
Operator: Thank you. And with that, ladies and gentlemen, we conclude our Q&A and program for today. Thank you all for participating. And you may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.